- Patients with advanced epidermal growth factor receptor (EGFR)-mutant NSCLC who took aspirin while undergoing treatment with osimertinib had significantly better PFS than those who did not take aspirin.
Why this matters
- Studies have suggested a protective benefit of aspirin against incidence, metastasis, or death from certain types of cancer, but its effect on EGFR-positive NSCLC is understudied.
- 365 patients with advanced EGFR-mutant NSCLC treated with osimertinib, 77 of whom received concomitant aspiring for ≥1 month.
- Funding: University of Texas MD Anderson Cancer Center.
- Patients in the aspirin group had a lower incidence of central nervous system (CNS) metastases before osimertinib treatment (27% vs 43%; P=.013) and were older (median age, 69 vs 62 years; P<.001>
- Median PFS was significantly longer in the aspirin group (HRs):
- Overall (21.3 vs 11.6 months): 0.52 (P<.001>
- With first-line osimertinib: 0.35 (P=.007).
- With second- or later-line osimertinib: 0.50 (P=.002).
- Among those with CNS metastases: 0.43 (P=.006).
- Among those without CNS metastases: 0.50 (P=.005).
- Retrospective, single-center study.